London (UK), November 21st 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology company pioneering first-in-class therapies targeting the unique metabolism of cancer cells, is pleased to announce that Sphene Capital, the highly respected European independent analyst house, has once again issued a “Buy” recommendation for Vidac Pharma’s shares. The reaffirmed rating comes with no change in the analyst’s GBP-based valuation of the Company. The target price has been adjusted slightly from €4.20 to €4.10 per share, reflecting currency movements between the British Pound and Euro, while maintaining confidence in the Company’s long-term value.
This renewed “Buy” recommendation follows the recent regulatory authorization in Germany to initiate Vidac Pharma’s new Phase 2 clinical study in actinic keratosis (AK), focusing specifically on highly proliferative lesions—a clinically significant patient segment with considerable unmet need.
Dr. Max Herzberg, Founder and CEO of Vidac Pharma, commented:
“We are proud that a high-quality analyst group such as Sphene Capital, through their understanding of our science, recognizes the importance of this new claim for our future market positioning. Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial.”
Vidac Pharma remains committed to advancing its innovative Tuvatexib (VDA-1102) platform as it continues to develop first-in-class therapies addressing the abnormal metabolic pathways of cancer and pre-cancerous skin lesions.
For more information please contact:
|
Vidac Pharma Holding Plc investors@vidacpharma.com |
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.